ShangBay Capital is a venture capital company that brings both U.S. and global investors access to best-in-class investments in the U.S. medical devices, biotechnology, and digital health sectors through early-stage venture equity participation. Since our establishment in 2015, we have invested in over 50+ portfolio companies and have been ranked as the Most Active Medical Device VC across both the U.S. and Europe in 2020 and 2021.
External link for ShangBay Capital
1555 Alma Street
Palo Alto, California 94301, US
ShangBay Capital reposted this
Today, Tvardi is announcing its proposed reverse merger with Cara Therapeutics to continue developing novel treatments targeting STAT3 to treat fibrosis-driven diseases. We look forward to leveraging our combined resources as we advance our STAT3 inhibitor platform through Phase 2 studies in idiopathic pulmonary fibrosis and hepatocellular carcinoma. Read the full press release here: https://lnkd.in/gv6kRe8r
Congratulations Fluid Biomed Inc. on closing your $27 million Series A financing round! The round was co-led by Amplitude Ventures and an undisclosed strategic partner, with additional support from IAG Capital Partners, LifeArc Ventures, and returning investors ShangBay Capital and METIS Innovative. https://lnkd.in/gD4XN7Cp
ShangBay Capital reposted this
Congratulations Dr. Brandon M. Jones, Dr. Logan Vincent, and the entire Providence team on your 1st Laplace TTVR case! Todd Mortier Jenny Barba William Dai Ryan Spanheimer Morgan Evans Engage Venture Partners ShangBay Capital Features Capital
Medical Director, Structural Heart Program, Providence Valve Center, Portland, OR
Very excited for our first Transcatheter Tricuspid Valve replacement with the Laplace Interventional TTVR device. Right IJ approach, very intuitive deployment. Another Pacific Northwest first at Providence St. Vincent Valve Team. Logan Vincent, MD, Ramji Iyer, Dan Oliver, Kashish Goel, Lucas Schneider, Gunnar Askegaard, Pradeep Yadav, Thomas E. Waggoner, DO, FACC, FSCAI, FSVM, RPVI, Azeem Latib, Ethan Korngold, Steven Yakubov, Tara Timothy, Laplace Interventional
After demonstrating 72% reduction in huntingtin (HTT) mRNA with SKY-0515 in the healthy volunteer portion of their Phase 1 study, Skyhawk Therapeutics has received approval from the Australian Human Research Ethics Committees (HREC) to extend treatment for Huntington's patients up to 12 weeks. https://lnkd.in/gPHQkv9j
SetPoint Medical, ShangBay’s portfolio company, has just filed its PMA application to the FDA for the SetPoint System, a potential first-of-its-kind neuroimmune modulation device for adults living with moderate-to-severe rheumatoid arthritis. https://lnkd.in/gPXbQ9Yz
ShangBay Capital reposted this
Taking the stage during Day 2 at #InnovationSanDiego for “The Dynamics of Venture Investing Today” panel session moderated by David Cassak of MedTech Strategist: Erik Engelson, Venture Partner, ShangBay Capital Thomas Shehab, MD, MMM, Managing Partner, Arboretum Ventures Amrinder Singh, Partner, Vensana Capital Erik Engelson is President & CEO of Dragon Medical, Inc, a Venture Partner with ShangBay Capital and was recently the President & CEO of Lucira Health, Inc. (now part of Pfizer). Just prior, he was CEO of Medina Medical, which he sold to Medtronic. Tom Shehab draws upon his extensive experience as a physician and healthcare executive to identify medical device and health IT companies that improve patient outcomes and decrease costs. Amrinder Singh is a Partner at Vensana Capital. Amrinder was previously a Senior Investment Director at Medtronic Ventures where he supported new investments in the medical device, diagnostics, and digital health spaces along with providing operational and board management support to portfolio companies. Remain informed on new articles, conference updates and more with our helpful #medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI
ShangBay Capital reposted this
Inquis Medical, Inc. Medical closed a $40 million Series B financing round led by Marshall Wace. Existing investors ShangBay Capital, Yu Star, EnPointe Ventures and Pierre Lamond all participated in the oversubscribed round. 💬 "This is a strong validation of the confidence investors have in our mission and the potential impact of our innovations,” said Vahid Saadat, co-CEO and co-founder. Mojgan Saadat added: “We are excited for the next phase of the company and look forward to enhancing patient care by empowering physicians with our unique technology.” 🔗 Read more: https://lnkd.in/ddazP8YQ #MedicalDevice #MedTech #MedicalEquipment #HealthTech #SeriesA #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #FundingRound #AngelInvestment #GSCapitalConnect
ShangBay Capital reposted this
Exciting news! We are thrilled to announce that Zenflow has secured a $24M Series C financing round! This investment will be used to support our PMA submission and to prepare for commercialization of the Spring® System, a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH). The round includes new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Read our press release: https://bit.ly/3Ofn0tp #BPH #urology #menshealth
ShangBay Capital reposted this
We're excited to announce late-breaking data from the RESET-RA study at the American College of Rheumatology’s #ACR24. New positive data through 24 weeks of follow-up support SetPoint System's potential as a first-of-its-kind neuroimmune modulation treatment for adults living with rheumatoid arthritis (RA). “The results from the RESET-RA study, highlighting improvements in disease severity and joint protection, underpin the continued positive clinical impact of neuroimmune modulation as a potential novel treatment for rheumatoid arthritis,” said John Tesser, MD, FACP, FACR, MACR of Arizona Arthritis & Rheumatology Associates, PC in Phoenix, AZ, and national rheumatologist principal investigator of the study. Learn more about the late-breaking data in today's press release: https://lnkd.in/eHeAMRkk #TheSetPointAdvantage #RheumatoidArthritis #RA This communication contains information about a device not yet approved in the United States for commercial use. The Setpoint System is limited by United States law to investigational use only.